AJH 1999;12: Downloaded from by guest on 15 December 2018
|
|
- Joseph Phelps
- 5 years ago
- Views:
Transcription
1 AJH 1999;12: Differential Effects of Morning and Evening Dosing of Nisoldipine ER on Circadian Blood Pressure and Heart Rate William B. White, George A. Mansoor, Thomas G. Pickering, Donald G. Vidt, Howard G. Hutchinson, Roger B. Johnson, and Robert Noveck The time of administration of once-daily antihypertensive agents may have a significant impact on blood pressure control during awake and sleep periods. Using 24-h ambulatory monitoring, we compared the effects of morning and evening dosing of the long-acting dihydropyridine calcium channel blocker, nisoldipine extended-release (ER), on circadian blood pressure (BP) and heart rate in patients with mild-to-moderate hypertension. After completing a 3-week placebo run-in period, 85 patients were randomized to morning versus evening nisoldipine ER treatment at a fixed 20-mg dose. Patients were treated for 4 weeks, followed by crossover to the alternate dosing regimen for 4 additional weeks. Twenty-four hour ambulatory monitoring was performed at baseline and at 4 and 8 weeks after randomization. Awake and sleep times were determined by electronic activity recorders (Actigraphy). Similar least-squares ( SE) mean changes from baseline in 24-h BP (systolic BP/diastolic BP: 11.9/ /0.5 v 11.6/ /0.5 mm Hg) and heart rate (1.0/ /0.4 beats/min) occurred with morning and evening administration, respectively. A significantly greater effect on awake diastolic BP (systolic BP/diastolic BP: 12.6/ /0.4 v 11.3/ /0.4 mm Hg; P.16/.01) was observed with morning dosing compared with evening dosing. In addition, small increases in sleep and early morning heart rate were seen with evening compared with morning administration of nisoldipine (sleep, v beats/min; P <.001; early morning, v beats/min; P.002). These differential effects on awake BP and sleep heart rate were also observed in patients who had normal (dippers) and elevated (nondippers) BP values during sleep. Appropriate evaluation of the efficacy and safety of long-acting antihypertensive agents is essential when evening administration is being considered. In the present study, the timing of nisoldipine ER administration had no effect on mean changes in BP and heart rate over a 24-h period. However, nisoldipine ER had some differential effects during sleep and awake periods with morning relative to evening dosing. Am J Hypertens 1999;12: American Journal of Hypertension, Ltd. KEY WORDS: Hypertension, ambulatory blood pressure monitoring, circadian rhythm, nisoldipine ER, morning and evening administration. Received August 21, Accepted January 5, From the University of Connecticut School of Medicine, Farmington, Connecticut (WBW, GAM); Cornell University Medical College, New York Hospital, New York, New York (TGP); Cleveland Clinic, Cleveland, Ohio (DGV); Medical Affairs Department, Zeneca Pharmaceuticals, Wilmington, Delaware (HGH, RBJ); and Tulane School of Medicine, New Orleans, Louisiana (RN). Support was provided by the National Institutes of Health General Clinical Research Grant MOI-RR and by grants from Zeneca Pharmaceuticals and the Patrick and Catherine Weldon Donaghue Medical Research Foundation. Address correspondence and reprint requests to William B. White, MD, Professor of Medicine and Chief, Section of Hypertension and Clinical Pharmacology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT by the American Journal of Hypertension, Ltd /99/$20.00 Published by Elsevier Science, Inc. PII S (99)
2 AJH AUGUST 1999 VOL. 12, NO. 8, PART 1 MORNING V EVENING DOSING OF NISOLDIPINE 807 The effects of time of dosing on the pharmacodynamics of long-acting, once-daily antihypertensive drugs are an important consideration for antihypertensive therapeutics. 1 Studies using ambulatory monitoring of blood pressure (BP) and heart rate have shown that altering the dosing time of antihypertensive agents may have a clinically meaningful effect on nocturnal BP. 2 4 In addition, some agents given once or twice daily may not provide adequate BP control, and the antihypertensive effect of some agents may taper by the end of a 24-h period. 3,5 Thus, it is appropriate to perform studies with once-daily hypertensive therapies to evaluate the effects of dosing time on circadian BP and heart rate. Nisoldipine is a potent vascular-selective dihydropyridine calcium antagonist used in the treatment of hypertension. To optimize the drug s time-effect profile over the 24-h dosing period, nisoldipine was developed in a coat-core, extended-release (ER) formulation. 6 After oral administration of nisoldipine ER, drug concentration increases for 6 to 12 h, and then a plateau is maintained for up to 24 h. 6,7 The elimination half-life of nisoldipine ER ranges from 7 to 12 h. Nisoldipine ER provides 24-h antihypertensive efficacy when administered in the morning, typically in a fasting state. 8 To investigate whether time of administration influences the 24-h efficacy of nisoldipine ER, we performed a double-blind, crossover study using ambulatory monitoring of BP and heart rate in patients with essential hypertension. MATERIALS AND METHODS Study Patients The study protocol and consent forms were approved by the institutional review boards of the various centers, and all patients provided written informed consent. Men and women, 21 years of age or older, with stage I or II hypertension defined by the criteria of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI) were eligible for the study. 9 Patients were included if the average of three seated office DBP measurements after 5 min of rest was 90 and 109 mm Hg at the end of the singleblind, placebo run-in period. Key exclusion criteria were any known form of secondary hypertension, systolic BP 200 mm Hg or diastolic BP 110 mm Hg; bradycardia (heart rate 45 beats/min) or tachycardia (heart rate 100 beats/ min), stroke or myocardial infarction in the previous 6 months, congestive heart failure (left ventricular ejection fraction 40%), clinically significant hepatic or renal disease, uncontrolled diabetes mellitus, life-style factors such as night-shift work or regular naps during the daytime, or history of allergy or intolerance to study medications. Study Design The study had a randomized, doubleblind, crossover design that included a 3-week, singleblind, placebo run-in phase and an 8-week doubleblind active treatment phase (Figure 1). Patients who successfully completed the baseline screening period entered the run-in period and received placebo in the FIGURE 1. The study design was double-blind, double-dummy, and crossover; ambulatory BP recordings were performed at the end of placebo baseline and after 4 and 8 weeks of double-blind morning or evening nisoldipine ER treatment.
3 808 WHITE ET AL AJH AUGUST 1999 VOL. 12, NO. 8, PART 1 morning and evening. After completing the run-in period, patients were randomly assigned to receive morning or evening administration of 20 mg nisoldipine ER for 4 weeks. The actual treatment given to each patient was determined at each center by a randomization schedule, and patients were allocated to treatment in balanced blocks. Patients in one group received nisoldipine ER in the morning (between 7 am and 9 am) and matching placebo in the evening (between 9 pm and 11 pm), whereas those in the other group received matching placebo in the morning and nisoldipine ER in the evening. After receiving 4 weeks of active therapy, the patients then received nisoldipine ER by the alternate dosing schedule for 4 weeks. Patients were instructed to fast for 1 h before and after taking study medication, and to take their medication at the same time each day, regardless of scheduled office visits or ambulatory BP monitoring. The effects of nisoldipine ER after morning and evening administration were assessed by determining changes in 24-h ambulatory BP and heart rate and office BP and heart rate. Ambulatory Blood Pressure Recordings Twentyfour hour ambulatory BP and heart rate were measured with SpaceLabs monitors (Redmond, WA). 10 Ambulatory BP was measured 24 h before randomization and 24 h before the last day of treatment during the two active treatment periods. Patients were fitted with a monitor on the same arm used for office BP determinations, with cuff size adapted to the arm circumference. All monitors were compared against a standard mercury sphygmomanometer to ensure that office diastolic BP and ambulatory BP were in agreement ( 7 mm Hg). BP and heart rate were recorded every 15 min over the 24-h period. Successful monitoring occurred when 80% of readings were valid over the monitoring period, including a minimum of two valid readings/h (with an allowance for a maximum of two nonconsecutive h of missing data) and at least 4hofvalid measurements after patients awakened in the morning. If these criteria were not satisfied, the monitoring study could be repeated. The time of dosing of medication, sleep, and awakening were recorded on diary cards. A Mini Motionlogger Actigraph (Ambulatory Monitoring Inc., Ardsley, NY), a wristwatch-sized device that records motion, was attached to the wrist of the other arm and used to determine sleep and awake times. 11 It provides an objective determination of sleep times by a built-in algorithm, or by use of an event marker button activated by a patient when retiring or awakening. Each activity monitor was synchronized with the ambulatory BP monitor time at the start of recording. Patients were instructed to activate the recorder before sleeping and after awakening. The times TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS Gender, n (%) Women 32 (43) Men 43 (57) Mean age, years (SD) 57.8 (9.1) Race, n (%) White 46 (61) Black 26 (35) Hispanic 2 (3) Asian 1 (1) Mean weight, kg (SD) Women 77.3 (14.0) Men 85.4 (15.5) Office blood pressure Systolic BP, mm Hg (SD) (13.9) Diastolic BP, mm Hg (SD) 97.3 (5.0) Heart rate, beats/min (SD) 75.5 (10.0) determined from these Actigraph recordings were the primary data used for sleep and awake BP and heart rate analyses, and diary card information was used when activity monitor data could not be interpreted. It has been demonstrated that more precise values are obtained for both mean sleep BP and sleep BP loads when actual times of wakefulness and sleep are used rather than arbitrary times of daytime and nighttime. 12 In addition, electronic activity improves the ability to obtain objective and precise times of wakefulness and sleep, 13 which is of relevance in a study that assesses the chronobiologic impact of antihypertensive drug dosing times. Statistical Analyses The primary objective was to evaluate whether 24-h BP changes with nisoldipine ER were independent of the time of nisoldipine administration, such that the mean reductions in diastolic 24-h ambulatory BP were equivalent for both morning and evening dosing. On the basis of a maximum difference in response between dosing schedules acceptable for clinical equivalence of 3.4 mm Hg, with a.05 level of significance and 80% testing power, the total sample size required was 60 patients. The sample size was based on an estimated within-subject standard deviation of 6.3 mm Hg for 24-h diastolic ambulatory BP. 14 An analysis of variance (ANOVA) model for a crossover design was used to demonstrate equivalence between the two treatment regimens for the primary endpoint. 15 The model included terms for sequence group, patient within sequence group, period, and treatment. The test for unequal carryover effect was performed by testing for the effect of sequence group using the patients within sequence group mean square as the denominator of the F-ratio, whereas period and treatment were tested using the within-patient residual mean square as the denomina-
4 AJH AUGUST 1999 VOL. 12, NO. 8, PART 1 MORNING V EVENING DOSING OF NISOLDIPINE 809 TABLE 2. BASELINE CHARACTERISTICS OF DIPPERS AND NONDIPPERS Systolic Criteria Dippers (n 39) Nondippers (n 36) Diastolic Criteria Dippers Nondippers (n 56) (n 19) Gender, n (%) Women 14 (36) 18 (50) 24 (43) 8 (42) Men 25 (64) 18 (50) 32 (57) 11 (58) Mean age, years (SD) 57.7 (10.1) 58.0 (8.0) 57.2 (9.8) 59.7 (6.8) Race, n (%) White 29 (74) 17 (47) 37 (66) 9 (47) Black 8 (21) 18 (50) 16 (29) 10 (53) Other 2 (5) 1 (3) 3 (5) 0 (0) tor. 15 A 90% confidence interval, which was equivalent to using two one-sided tests, each with a significance level of.05, was generated from the ANOVA model to assess treatment equivalence. This primary analysis included all randomized patients who had evaluable 24-h ABP data at baseline and after the two treatment phases. Secondary objectives were to evaluate the mean change from baseline in systolic 24-h ABP; in systolic and diastolic ABP during awake, sleep, and early morning periods (4 h after awakening); and systolic and diastolic ABP in dippers and nondippers. Dippers were defined as patients whose mean systolic BP decreased by 10% during sleep compared with awake BP values. Nondippers were patients whose sleep systolic BP declined by 10%. 16 Dippers and nondippers were also defined by a second criterion that used diastolic BP changes instead of systolic BP changes during the sleep and awake periods. The secondary efficacy endpoints were analyzed in the same manner as the primary endpoint, and patients included in the analyses of the secondary endpoints had to meet the same requirements as for patients included in the primary analysis. Systolic BP, diastolic BP, and heart rate during the early morning were calculated by averaging all BP and heart rate data points from the 4-h period after the awake times determined by Actigraphs. Comparisons of the dipper and nondipper subgroups were done separately for morning and evening administration. These comparisons were done using an ANOVA model with terms for period and dipper classification. RESULTS Demography and Pretreatment Characteristics Eighty-five patients were randomized to treatment with morning or evening administration of nisoldipine. Seventy-five patients were evaluable after completing the two active treatment periods (Table 1). Ten patients were withdrawn from the study after randomization: eight for adverse events (most commonly peripheral edema and headache) and two were lost to follow-up. Demographic characteristics of dippers and nondippers are displayed for both systolic and diastolic BP criteria (Table 2). According to systolic BP and diastolic BP criteria, about 25 35% of white hypertensives were nondippers, whereas 40 70% of black hypertensives were nondippers. TABLE 3. AMBULATORY BP AND HEART RATE ACCORDING TO DOSING TIME (N 75) Hour Baseline (Mean SD) Morning Dosing LS Mean Change (Mean SE) Evening Dosing LS Mean Change (Mean SE) Difference ( SE) (90% CI) P value Systolic BP ( ).66 Awake ( ).16 Sleep ( ).13 Early morning* ( ).11 Diastolic BP ( ).16 Awake ( ).01 Sleep ( ).25 Early morning ( ).54 Heart Rate ( ).23 Awake ( ).89 Sleep ( ).001 Early morning ( ).002 * Average of first 4 h postawakening. LS, least-squares; SD, standard deviation; SE, standard error; CI, confidence interval.
5 810 WHITE ET AL AJH AUGUST 1999 VOL. 12, NO. 8, PART 1 FIGURE 2. Effect of morning versus evening dosing of nisoldipine ER on SBP over 24 hours. The uppermost panel displays SBP levels for baseline and for the two dosing times, whereas the lower panel shows the changes in SBP from baseline for the two dosing times. Efficacy There were no differences in least-squares (LS) mean ( SE) changes in 24-h BP or heart rate according to dosing time (Table 3). The differences in the LS mean ( SE) change from baseline in ambulatory systolic and diastolic BP and heart rate (morning minus evening administration) were mm Hg, mm Hg, and beats/min, with 90% confidence intervals of 1.9 to 1.1 mm Hg, 2.0 to 0.2 mm Hg, and 1.8 to 0.3 beats/min, respectively. The effects of morning and evening administration of nisoldipine ER on 24-h ambulatory systolic and diastolic BP profiles are shown in Figures 2 and 3. BP was lowered with both morning and evening administration of nisoldipine ER throughout the monitoring period, and there was equivalent mean 24-h BP reduction without affecting 24-h average heart rate (Table 3). As shown in Figure 4, 24-h heart rate profiles were similar after morning and evening administration. An evaluation of the sleep and awake periods revealed differential BP and heart rate effects for morning compared with evening dosing (Table 3). During the awake period, the antihypertensive effect of nisoldipine was greater after morning compared with evening administration (P.16 for systolic BP and P.01 for diastolic BP). Similarly, there was a trend for reductions in BP during sleep to be greater with nighttime compared with morning dosing. Both during sleep and in the early morning period, evening dosing of nisoldipine was associated with 2- to 3-beats/min increases in heart rate, compared with morning dosing. During the awake period, there were no differences in heart rate responses for morning compared with evening administration. The effects of morning and evening dosing of nisoldipine ER in systolic dippers and nondippers are shown in Table 4. Similar to the results in the overall population, the LS mean changes in 24-h BP and heart rate did not differ significantly between the two dosing regimens for these two groups. However, in both groups, reductions in awake BP were greater with morning dosing, and heart rate tended to increase during sleep with evening dosing. Independent of the time of administration, average reductions in BP over 24 h for nondippers treated with nisoldipine ER tended to be greater than those for
6 AJH AUGUST 1999 VOL. 12, NO. 8, PART 1 MORNING V EVENING DOSING OF NISOLDIPINE 811 FIGURE 3. Effect of morning versus evening dosing of nisoldipine ER on DBP over 24 hours. The uppermost panel displays DBP levels for baseline and for the two dosing times, whereas the lower panel shows the changes in DBP from baseline for the two dosing times. dippers (Table 4). With morning dosing, the 24-h LS mean ( SE) changes in BP were / mm Hg in nondippers and / mm Hg in dippers (P.17/P.03). With evening dosing, the values were / mm Hg and / mm Hg, respectively (P.09/P.13). Most of these differences are attributable to the much larger reductions in BP during sleep observed in nondippers compared with dippers. Patients were also classified as dippers and nondippers based on a diastolic BP classification similar to the systolic BP classification (Table 2). All diastolic nondippers were systolic nondippers. Despite the classification change, the overall results were similar to the results for the systolic dippers and nondippers (data not shown). DISCUSSION Principal Findings Our data demonstrate that nisoldipine ER has similar overall mean effects on 24-h BP and heart rate when administered in the morning and evening. However, differential effects were observed for awake and sleep periods with the different times of administration. These could be characterized as small reductions in awake diastolic BP after morning dosing compared with evening dosing and small increases in sleep and early morning heart rate after evening dosing compared with morning dosing. Finally, patients who were characterized as nondippers at baseline tended to have larger reductions in sleep BP compared with those patients characterized at baseline as dippers, regardless of time of dosing of nisoldipine ER. Effects of Timing of Dosing of Antihypertensive Therapy on Ambulatory BP: Sample Size Considerations Recently, investigators have begun to evaluate the effects of antihypertensive drugs on the circadian rhythms of blood pressure as they relate to drug pharmacokinetics at steady state, alteration of drug disposition by various delivery systems, and timing of drug dosing. 17,18 Although a fairly large number of studies have been performed to assess the impact of timing of dosing of therapy, most have had small sample sizes, open-label design, short treatment periods, or may not have used a crossover design that
7 812 WHITE ET AL AJH AUGUST 1999 VOL. 12, NO. 8, PART 1 FIGURE 4. Effect of morning versus evening dosing of nisoldipine ER on heart rate over 24 hours. The uppermost panel displays the heart rate values for baseline and for the two dosing times, whereas the lower panel shows the changes in heart rate from baseline for the two dosing times. allows for reduced error variability. 19 In our study, we prospectively calculated the sample size requirements for the present crossover design and took into consideration the variability of ambulatory BP as well as the desire to be able to detect 3.4-mm Hg differences between the dosing regimens on 24-hour diastolic BP. This power calculation demonstrated that at least 60 patients were required to demonstrate a 3.4-mm Hg difference in ambulatory diastolic BP between groups. A recent review 19 of the chronopharmacology of antihypertensive drugs revealed that 15 studies evaluating the effect of dosing time of several classes of agents on circadian BP rhythms had as few as six and a maximum of 20 total patients. Thus, most studies in this field have been greatly underpowered. Effects of Dosing Time of Antihypertensive Therapy on 24-h BP and Heart Rate Profiles Our study showed that morning dosing of nisoldipine induced lower awake diastolic BP compared with evening dosing (Table 3, Figure 3), whereas evening dosing of nisoldipine ER induced higher sleep heart rates compared with morning dosing (Table 3, Figure 4). These changes, although numerically modest, are likely to be related to the pharmacokinetics of the nisoldipine formulation. 6,8 When the tablet was administered in the morning, the ambulatory BP was lowered to a greater extent in the afternoon than when given in the evening (Figures 2, 3). Furthermore, when nisoldipine was administered in the evening, the ambulatory BP tended to be lower at night than when the drug was given in the morning (Figures 2, 3). Small increases in heart rate were also noted during sleep in patients who received nisoldipine in the evening. This may have occurred because of enhanced baroreflex sensitivity and reflex increases in heart rate that are often seen in the presence of arterial vasodilation during sleep. 20 Other studies comparing the effects of time of administration have been performed with the dihydropyridine calcium antagonists, nifedipine gastrointestinal therapeutic system (GITS), 21 and amlodipine. 22 In the nifedipine trial, patients were studied using 30 mg at either 10 am or 10 pm. 22 The treatment periods
8 AJH AUGUST 1999 VOL. 12, NO. 8, PART 1 MORNING V EVENING DOSING OF NISOLDIPINE 813 TABLE 4. AMBULATORY BP AND HEART RATE IN DIPPERS AND NONDIPPERS* Parameter Hour Baseline (Mean SD) Morning Dosing LS Mean D (Mean SE) Evening Dosing LS Mean D (Mean SE) P Value Dippers (n 39) Systolic BP Awake Sleep Diastolic BP Awake Sleep Heart rate Awake Sleep Nondippers (N 36) Systolic BP Awake Sleep Diastolic BP Awake Sleep Heart rate Awake Sleep * Dippers defined as a sleep systolic BP decline 10% compared with awake systolic BP. All others are classified as nondippers. Abbreviations same as Table 3. were 1 and 2 weeks, respectively. Nifedipine GITS did induce a 3- to 5-beats/min increase in ambulatory heart rate compared with placebo; however, this was not statistically significant, possibly because of the small sample size. Similarly, morning dosing lowered daytime BP slightly more than evening dosing, but this did not achieve statistical significance. Similar to the present study of nisoldipine ER, an evaluation of amlodipine by Mengden and coworkers 22 indicated that morning and evening dosing of the drug had little impact on mean 24-h BP control. However, evening dosing of amlodipine resulted in a significant increase in heart rate compared with baseline (73 7 v 77 10, P.05). Unlike our trial, there were only 20 patients in the comparison of the effect of amlodipine dosing time on 24-h BP and heart rate profiles, and the power of the study to show additional differences comes into question. Circadian Variation of BP and the Effects of Antihypertensive Therapy Recognition of the characteristics of the circadian variation of BP and heart rate has led to increased numbers of clinical trials that evaluate the effects of antihypertensive therapy on early morning, awake, and sleep blood pressures. The circadian pattern of BP typically is characterized by higher values during the awake and active period and lower BP and heart rate during sleep. However, this nocturnal decline in BP is blunted or absent in some hypertensive patients and their cardiovascular risks may be excessive. 16,23 Thus, it has become of interest to determine the effects of antihypertensive drugs on nocturnal BP in nondippers. In our patient population, approximately 25% to 35% of white hypertensives were nondippers, whereas 40% to 70% of black hypertensives were nondippers (Table 2). Both morning and evening dosing of nisoldipine induced substantially greater reductions in sleep BP in nondippers compared with dippers (Table 4). As a group, the nondippers were actually converted to dippers after administration of nisoldipine ER. Similar findings in nondippers versus dippers have been reported with a placebo-controlled trial of COER-verapamil 24 and in an open-label evaluation of amlodipine in older patients from Japan. 25
9 814 WHITE ET AL AJH AUGUST 1999 VOL. 12, NO. 8, PART 1 Conclusions Our data show that overall 24-h BP control is similar when nisoldipine is dosed in the morning versus the evening. Small, differential effects during the awake and sleep periods averaged out to yield reductions in 24-h BP within 1 mm Hg for the morning versus evening administration regimens. These data and those of other chronopharmacology studies show, however, that it is mandatory to perform a well-powered clinical trial using 24-h ambulatory BP monitoring to determine the effects of dosing time on the circadian BP and heart rate. Most longacting antihypertensive drugs were developed for morning dosing or split, twice-daily administration. Although it is likely that many drugs would be as effective and safe when administered at night as during the day, some agents may have substantially different effects on nocturnal BP 4 when given at bedtime versus upon awakening. Thus, unless the antihypertensive agent has been properly studied and safety and efficacy have been fully assessed, dosing before sleep is inadvisable. ACKNOWLEDGMENT We thank Gary Dorrell, MS, ELS and Kendall Wills Sterling, ELS, for editorial assistance. REFERENCES 1. White WB: A chronotherapeutic approach to the management of hypertension. Am J Hypertens 1996;10:29S 33S. 2. Lemmer B: Differential effects of antihypertensive drugs on circadian rhythm in blood pressure from chronobiologic point of view. Blood Press Monitor 1996;1: Pickering TG, Levenstein M, Walmsley P, et al: Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT study. Am J Hypertens 1994;6: Palatini P, Racioppa A, Raule G, et al: Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther 1992;52: Whelton A, Miller WE, Dunne B Jr, et al: Once-daily lisinopril compared with twice-daily captopril in the treatment of mild-to-moderate hypertension: assessment of office and ambulatory blood pressures. J Clin Pharmacol 1990;30: Zannad F: Clinical pharmacology of nisoldipine coat core. Am J Cardiol 1995;75:41E 45E. 7. Plosker GL, Faulds D: Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension. Drugs 1996;52: Opie LH, Muller FO, Myburg DP, et al: Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Am J Hypertens 1997;10: Joint National Committee: The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157: Cates EM, Schussel GD, Pickering TG: A validation study of the spacelabs ambulatory blood pressure monitor. J Ambul Monitor 1990;3: Cole RJ, Kripke DF, Gruen W, et al: Automatic sleep/ wake identification from wrist actigraphy. Sleep 1992; 15: Peixoto Filho AJ, Mansoor GA, White WB: Effects of actual versus arbitrary awake and sleep times on analyses of 24-hour blood pressure. Am J Hypertens 1995; 8: Mansoor GA, Peixoto A, White WB: Reproducibility of blood pressure and activity during the early morning BP surge. Blood Press Monitor 1996;1: Coats AJ, Conway J, Somers VK, et al: Ambulatory blood pressure monitoring in the assessment of antihypertensive therapy. Cardiovasc Drugs Ther 1989;3: Hills M, Armitage P: The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8: White WB, Mansoor GA, Tendler BE, et al: Nocturnal blood pressure: epidemiology, determinants, and effects of antihypertensive therapy. Blood Press Monitor 1998;3: White WB: Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics. Blood Press Monitor 1997;2: White WB: Ambulatory blood pressure in the evaluation of hypertension therapy. Cardiol Clin 1995;13: Lemmer B, Portaluppi F: Chronopharmacology of cardiovascular diseases, in Redfern PH, Lemmer B (eds): Handbook of Experimental Pharmacology, Vol 125, Physiology and Pharmacology of Biological Rhythms. Springer-Verlag, Berlin, 1997, pp Smyth HS, Sleight P, Pickering GW: Reflex regulation of arterial pressure during sleep in man. A quantitative method of assessing baroreflex sensitivity. Circ Res 1969;24: Greminger P, Suter PM, Holm D, et al: Morning versus evening administration of nifedipine gastrointestinal therapeutic system in the management of essential hypertension. Clin Invest 1994;72: Mengden T, Binswanger B, Gruene S: Dynamics of drug compliance and 24-hour blood pressure control of once daily morning versus evening amlodipine. J Hypertens 1992;10(suppl 4):S136 S Verdecchia P, Porcellati C, Schillaci G, et al: Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994;24: White WB, Mehrotra DV, Black HR, et al: Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). Am J Cardiol 1997;80: Kario K, Shimada K: Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Am J Hypertens 1997;10:
The incidence of transient myocardial ischemia,
AJH 1999;12:50S 55S Heart Rate and the Rate-Pressure Product as Determinants of Cardiovascular Risk in Patients With Hypertension William B. White Inability to supply oxygen to the myocardium when demand
More informationComparison of arbitrary definitions of circadian time periods with those determined by wrist actigraphy in analysis of ABPM data
Journal of Human Hypertension (1999) 13, 449 453 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Comparison of arbitrary definitions of
More informationANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*
Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationCalculation of Trough-to-Peak Ratio in the Research Unit Setting
A]H 1996; 9:71S-75S Calculation of Trough-to-Peak Ratio in the Research Unit Setting Advantages and Disadvantages Henry L. Elliott and Peter A. Meredith The trough-to-peak ratio for the response to an
More informationAGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston
AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK Michael Smolensky, Ph.D. The University of Texas Austin & Houston Disclosures Partner: Circadian Ambulatory Diagnostics Consultant: Spot On Sciences
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationTime of day for exercise on blood pressure reduction in dipping and nondipping hypertension
(2005) 19, 597 605 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE on blood pressure reduction in dipping and nondipping hypertension S Park,
More informationThere is convincing evidence in clinical studies
AJH 1998;11:1413 1417 Reliability of Reporting Self-Measured Blood Pressure Values by Hypertensive Patients Thomas Mengden, Rosa Maria Hernandez Medina, Belen Beltran, Elena Alvarez, Karin Kraft, and Hans
More informationEvaluation of the Extent and Duration of the ABPM Effect in Hypertensive Patients
Journal of the American College of Cardiology Vol. 40, No. 4, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02011-9
More informationAssessing Blood Pressure for Clinical Research: Pearls & Pitfalls
Assessing Blood Pressure for Clinical Research: Pearls & Pitfalls Anthony J. Viera, MD, MPH, FAHA Department of Family Medicine Hypertension Research Program UNC School of Medicine Objectives Review limitations
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationMorning Hypertension: A Pitfall of Current Hypertensive Management
Review Article Hypertension: A Pitfall of Current Hypertensive Management JMAJ 48(5): 234 240, 2005 Kazuomi Kario* 1 Abstract has recently attracted more attention because of the close relation between
More informationAmbulatory Blood Pressure Monitoring Clinical Practice Recommendations
Acta Medica Marisiensis 2016;62(3):350-355 DOI: 10.1515/amma-2016-0038 UPDATE Ambulatory Blood Pressure Monitoring Clinical Practice Recommendations Mako Katalin *, Ureche Corina, Jeremias Zsuzsanna University
More informationVerapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design
Br J Clin Pharmacol 1998; 45: 491 495 Verapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design Juergen Scholze, 1 Peter Zilles 2 & Daniele Compagnone 2 on
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information& Wilkins. a Division of Cardiology, Schulich Heart Centre, b Institute for Clinical and
Original article 333 Optimum frequency of office blood pressure measurement using an automated sphygmomanometer Martin G. Myers a, Miguel Valdivieso a and Alexander Kiss b,c Objective To determine the
More informationThe Evolution To Treatment Of Hypertension With Advanced Formulation
The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang High
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThe magnitude and duration of ambulatory blood pressure reduction following acute exercise
Journal of Human Hypertension (1999) 13, 361 366 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE The magnitude and duration of ambulatory
More informationAmbulatory BP Monitoring: Getting the Diagnosis of Hypertension Right. Anthony J. Viera, MD, MPH, FAHA Professor and Chair
Ambulatory BP Monitoring: Getting the Diagnosis of Hypertension Right Anthony J. Viera, MD, MPH, FAHA Professor and Chair Objectives Review limitations of office BP in making a correct diagnosis of hypertension
More informationOptimal timing for antihypertensive dosing: focus on valsartan
REVIEW Optimal timing for antihypertensive dosing: focus on valsartan Ramón C Hermida Diana E Ayala Carlos Calvo Bioengineering & Chronobiology Laboratories, University of Vigo, Campus Universitario, Vigo,
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationNormal Ambulatory Blood Pressure: A Clinical-Practice- Based Analysis of Recent American Heart Association Recommendations
The American Journal of Medicine (2006) 119, 69.e13-69.e18 CLINICAL RESEARCH STUDY Normal Ambulatory Blood Pressure: A Clinical-Practice- Based Analysis of Recent American Heart Association Recommendations
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationBaroreflex sensitivity and the blood pressure response to -blockade
Journal of Human Hypertension (1999) 13, 185 190 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Baroreflex sensitivity and the blood pressure
More informationChapter-V. Summary, Conclusions and Recommendations
Summary, Conclusions and Recommendations INTRODUCTION The work included in this thesis entitled, Circadian heart rate and blood pressure variability in apparently healthy subjects using ABPM has been divided
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDrug Class Review on Calcium Channel Blockers
Drug Class Review on UPDATED FINAL REPORT #1 April 2004 Marian S. McDonagh, PharmD Karen B. Eden, PhD Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Table of
More informationBlood Pressure Variability and Its Management in Hypertensive Patients
Korean J Fam Med. 2012;33:330-335 http://dx.doi.org/10.4082/kjfm.2012.33.6.330 Blood Pressure Variability and Its Management in Hypertensive Patients Review Hee-Jeong Choi* Department of Family Medicine,
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationArterial blood pressure (BP) increases with
AJH 1998;11:909 913 ORIGINAL CONTRIBUTIONS Estradiol-17 Reduces Blood Pressure and Restores the Normal Amplitude of the Circadian Blood Pressure Rhythm in Postmenopausal Hypertension Giuseppe Mercuro,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationTrough to peak ratio: current status and applicability
Journal of Human Hypertension (1998) 12, 55 59 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 REVIEW ARTICLE Trough to peak ratio: current status and applicability Department of Medicine
More informationThe Association of Daytime and Nighttime Ambulatory Blood Pressure with Carotid IMT When Controlling for Daytime Physical Activity.
The Association of Daytime and Nighttime Ambulatory Blood Pressure with Carotid IMT When Controlling for Daytime Physical Activity by Jeanette Garcia BS, University of Pittsburgh, 2004 MS, University of
More informationIndirect ambulatory blood pressure monitoring devices
AJH 1992;5:880-886 Comparison of Ambulatory and Clinic Blood Pressure and Heart Rate in Older Persons With Isolated Systolic Hypertension Gale H. Rutan, Robert H. McDonald, and Lewis H. Kuller We compared
More informationHypertension is a common disease in our
AJH 2000;13:1161 1167 Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on or Trefor O. Morgan, Adrianne Anderson, and Denise Bertram Arthritis and
More informationSTATE OF THE ART BP ASSESSMENT
STATE OF THE ART BP ASSESSMENT PROFESSOR MOLECULAR PHARMACOLOGY CONWAY INSTITUE UNIVERSITY COLLEGE DUBLIN CO-CHAIRMAN BLOOD PRESCSURE MANAGEMENT IN LOW RESOURCE SETTINGS CENTRE FOR INTERNATIONAL HUMANITARIAN
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationHow well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study
(2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?
More information...SELECTED ABSTRACTS...
The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationDrug Class Review on Calcium Channel Blockers FINAL REPORT
Drug Class Review on Calcium Channel Blockers FINAL REPORT September 2003 TABLE OF CONTENTS Introduction 5 Scope and Key Questions 6 Methods 6 Literature Search 6 Study Selection 6 Data Abstraction 7 Validity
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationHypertension is a risk factor for coronary
Original Paper Comparative Efficacy of Two Different b-blockers on 24-Hour Blood Pressure Control Pantelis Sarafidis MD, PhD; 1,2 Zvezdana Bogojevic, MD; 1 Emad Basta, MD; 1 Emily Kirstner, PhD; 3 George
More informationAzelnidipine and Amlodipine: a Comparison of Their Pharmacokinetics and Effects on Ambulatory Blood Pressure
201 Original Article Azelnidipine and Amlodipine: a Comparison of Their Pharmacokinetics and Effects on Ambulatory Blood Pressure Kizuku KURAMOTO, Shuichi ICHIKAWA 1, Aizan HIRAI 2, Shigeto KANADA 3, Tetsu
More informationChronobiology in Dysautonomia and Cerebrovascular Disease
Progress in Clinical Medicine Chronobiology in Dysautonomia and Cerebrovascular Disease JMAJ 44(4): 171 176, 2001 Tsutomu KAMO* and Yoichi TAKAHASHI** *Assistant Professor and **Associate Professor, Department
More informationThe accurate measurement of blood pressure
Position Paper ASH Position Paper: Home and Ambulatory Blood Pressure Monitoring When and How to Use Self (Home) and Ambulatory Blood Pressure Monitoring Thomas G. Pickering, MD, D Phil; 1 William B. White,
More informationSummary of recommendations
Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationPrognostic significance of blood pressure measured on rising
(2001) 15, 413 417 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured on rising P Gosse, C Cipriano,
More informationPhase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018
Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationPROFESSOR OF MEDICINE
PRINCIPAL INVESTIGATOR: WHITE, WILLIAM B BIOGRAPHICAL SKETCH Provide the following information for the key personnel and consultants and collaborators. Begin with the principal investigator/program director.
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationInhibitory Effects of Azelnidipine Tablets on Morning Hypertension
Drugs R D (2013) 13:63 73 DOI 10.1007/s40268-013-0006-8 ORIGINAL RESEARCH ARTICLE Inhibitory Effects of Azelnidipine Tablets on Morning Hypertension Kazuomi Kario Yuki Sato Masayuki Shirayama Megumi Takahashi
More informationAngiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Arterial Hypertension*
The Journal of International Medical Research 2005; 33 (Suppl 1): 21A 29A Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationIJRPC 2011, 1(3) Patel et al. ISSN: INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article EVALUATION OF COMPLIANCE AND BLOOD PRESSURE REDUCTION IN PATIENTS TREATED WITH AMLODIPINE
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationManaging Hypertension in the Perioperative Arena
Managing Hypertension in the Perioperative Arena Optimizing Perioperative Management Strategies for Hypertension in the Cardiac Surgical Patient Objectives: Treatment of hypertensive emergencies. ALBERT
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationNight time blood pressure and cardiovascular structure in a middle-aged general population in northern Italy: the Vobarno Study
(2001) 15, 879 885 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Night time blood pressure and cardiovascular structure in a middle-aged general
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationBlood Pressure Management in Acute Ischemic Stroke
Blood Pressure Management in Acute Ischemic Stroke Kimberly Clark, PharmD, BCCCP Clinical Pharmacy Specialist Critical Care, Greenville Health System Adjunct Assistant Professor, South Carolina College
More informationHypertension is a common medical disorder, affecting. Is Resistant Hypertension Really Resistant? Mark A. Brown, Megan L. Buddle, and Allison Martin
AJH 2001; 14:1263 1269 Is Resistant Hypertension Really Resistant? Mark A. Brown, Megan L. Buddle, and Allison Martin Background: Managing resistant hypertension is difficult and mostly involves expensive
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationThe management of hypertension has become
AJH 1997;10:743 749 Additive Effects of Diltiazem and Lisinopril in the Treatment of Elderly Patients With Mild-to-Moderate Hypertension Paul Chan, Chun-Nan Lin, Brian Tomlinson, Tz-Hsin Lin, and Ying-Shiung
More informationand bias, which are known to be present in self-home and in professional office BP measurements taken using the auscultatory technique [7].
Devices and technology 37 Validation of the A&D UM-11 professional hybrid device for office blood pressure measurement according to the International Protocol George S. Stergiou, Periklis P. Giovas, Charilaos
More informationHypertension, which is a widely prevalent and treatable
Chronic Kidney Disease and Nocturia Nocturia, Nocturnal Activity, and Nondipping Rajiv Agarwal, Robert P. Light, Jennifer E. Bills, Lindsey A. Hummel Abstract Patients with chronic kidney disease have
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationNon-dipping morning blood pressure and isolated systolic hypertension in elderly
DOI: 10.4149/BLL_2013_033 Bratisl Lek Listy 2013; 114 (3) CLINICAL STUDY Non-dipping morning blood pressure and isolated systolic hypertension in elderly Zain-El Abdin MH, Snincak M, Pahuli K, Solarova
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationPrognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice
(2005) 19, 801 807 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured in the office, at home and
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY. Introduction. Patients and Methods
Vol. 2, Issue 1, pages 31-36 ORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY By Alejandro de la Sierra, MD Luis M. Ruilope, MD Hypertension Units, Hospital Clinico, Barcelona & Hospital 12 de Octubre,
More informationAmbulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease. Rajiv Agarwal, MD
Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease Rajiv Agarwal, MD Summary: Hypertension is an important risk factor for adverse cardiovascular and renal outcomes, particularly
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationA Placebo-Controlled, Forced Titration Study. Yves Lacourcière and Roland Asmar for the Candesartan/Losartan study investigators
AJH 1999;12:1181 1187 A Comparison of the Efficacy and Duration of Action of Candesartan Cilexetil and Losartan as Assessed by Clinic and Ambulatory Blood Pressure After a Missed Dose, in Truly Hypertensive
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationCircadian rhythm of blood pressure is transformed from a dipper to a non-dipper pattern in shift workers with hypertension
(2002) 16, 193 197 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Circadian rhythm of blood pressure is transformed from a dipper to a non-dipper
More informationChronopharmacotherapy of Hypertension: Time-dependent effects of treatment on blood pressure
18 Review Article Chronopharmacotherapy of Hypertension: Time-dependent effects of treatment on blood pressure Suresh Rewar 1 *, Bansal BK 1, Singh CJ 2, Sharma AK 2 1 Department of pharmaceutics, Arya
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More information